Tempus AI Inc. (NASDAQ:TEM) reported second-quarter financial results Friday. The AI-focused precision medicine and patient ...

Tempus AI, Inc., a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has completed its acquisition of Ambry Genetics, a recognized ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

Aliso Viejo-based Ambry Genetics Corp. on Nov. 4 announced an agreement to be acquired for $600 million by Tempus AI Inc. “They’ve achieved one of the rare things in our space where you actually have ...

Tempus AI's growth in precision oncology drives an 80% revenue boost by 2025. Click here to find out why I rate TEM stock a Buy.

TD Cowen served as the sole financial advisor representing Tempus in the purchase of Ambry Genetics. Morgan Stanley, J.P. Morgan, and Allen & Company LLC represented the company in security financing.

Written by Zacks Equity Research for Zacks -> Shares of Tempus AI TEM gained 18.4% after it announced an agreement, on Nov. 4, 2024, to acquire Ambry Genetics for $600 million.

In trading on the Nasdaq stock market as of 1:17 p.m. Central, Tempus' stock price was trading at $60.65, up 3.2% from the ...

Tempus AI, Inc. TEM reported a second-quarter 2025 adjusted loss of 22 cents per share, narrower than the Zacks Consensus ...

Tempus AI, Inc. TEM is scheduled to report second-quarter 2025 results on Aug. 8. In the last reported quarter, the company’s adjusted loss of 24 cents was narrower than the Zacks Consensus Estimate ...

Aliso Viejo-based Ambry Genetics Corp., Orange County’s third-largest medical diagnostics and testing company, has entered into an agreement to be acquired for $600 million by Tempus AI Inc., which is ...